Background {#Sec1}
==========

The World Health Organization has recently identified antimicrobial resistance as one of the three most important problems facing human health. The most common and serious multidrug-resistant pathogens have been encompassed within the acronym "ESKAPE", which stands for *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacter* spp. \[[@CR1]\]. *Acinetobacter baumannii* is an important opportunistic nosocomial pathogen that is often associated with epidemic outbreaks of infection. This organism is frequently pandrug-resistant and is capable of causing substantial morbidity and mortality in patients with severe underlying disease, both in the hospital and in the community \[[@CR2]\]. *Acinetobacter baumannii* is an uncommon but important cause of community-acquired pneumonia, which appears to be a unique clinical entity occurring predominantly in tropical climates. This community-acquired pneumonia appears to be characterized by a fulminant course, with acute onset of dyspnea, cough and fever followed by rapid progression to respiratory failure and shock. The mortality rate is high (40--64 %) \[[@CR3], [@CR4]\]. Nosocomial pneumonia is the most important infection caused by *A. baumannii* and is particularly associated with the application of mechanical ventilatory procedures \[[@CR5]\]. The crude mortality rate associated with nosocomial Acinetobacter infections has been reported to range from 20 to 45 % \[[@CR6], [@CR7]\]. A prospective study of 240 *A. baumannii* infections showed that \> 90 % of infections were nosocomially acquired and that only 4 % were community acquired; moreover, respiratory track infections were the most common (39.3 %) \[[@CR8]\]. *Acinetobacter baumannii* has a propensity to cause outbreaks, probably because of its ability to survive desiccation and its multidrug resistance, amongst other reasons \[[@CR9]\]. Although *A. baumannii* is only rarely isolated from soil, vegetables, animals, humans and inanimate surfaces that are often in contact with humans \[[@CR10]\], the natural habitats of *A. baumannii* remain to be established \[[@CR11]\]. In the community, *A. baumannii* is a rare colonizer of human skin in temperate climates, although skin carriage is more common in tropical environments \[[@CR12], [@CR13]\]. In Australia, wet-season throat carriage of *A. baumannii* was found in 10 % of community residents with excess levels of alcohol consumption \[[@CR3]\]. The bacterium is ubiquitous in the hospital setting (*e.g.*, bedside, bedrail, ventilator, infusion pump, pillow, resuscitation equipment, washbasins) \[[@CR14], [@CR15]\]. Furthermore, *A. baumannii* is found to persist as a contaminant of the hands, gloves and gowns of healthcare workers \[[@CR16], [@CR17]\]. This bacterium can survive on inanimate objects for long periods, even after exposure to dry conditions \[[@CR18]\] and is also capable of resisting physical and chemical disinfection, often by forming a biofilm \[[@CR19]\]. It has a remarkable ability to up-regulate or acquire resistance determinants, making it one of the most important microorganisms threatening the current antibiotic era \[[@CR11]\]. Numerous outbreaks of pandrug-resistant *A. baumannii* have been documented in Asian and Middle East hospitals. Resistance to both tigecycline and polymyxin B (drugs relied on heavily to treat infection with *A. baumannii*) already exists in these regions \[[@CR20], [@CR21]\].

The first genome of an *Acinetobacter* spp. to be sequenced was that of the highly transformable *Acinetobacter* spp. strain ADP1 in 2004 \[[@CR22]\]. The first completed *A. baumannii* genome was reported for strain ATCC 17978 in 2007 and included a considerable number of the island-containing genes (16) implicated in virulence, indicating that several of the microorganism's genes are devoted to pathogenesis. The largest island contains elements homologous to the *Legionella*/*Coxiella* Type IV secretion apparatus. Type IV secretion systems have been demonstrated to be important for virulence in other microorganisms and are thus likely to help mediate the pathogenesis of *A. baumannii* \[[@CR23]\]. Several extracellular proteins of *A. baumannii*, grown *in vitro*, have been identified by the use of different proteomic approaches \[[@CR24], [@CR25]\]. Such approaches have been used for membrane and cytoplasmic proteomic analysis of *A. baumannii* grown *in vitro* \[[@CR26]--[@CR30]\]. Comparative proteomic analysis has been performed with cells at three different stages of *in vitro* growth: exponential, late stationary phase and as biofilms \[[@CR31]\]. Comparative proteomic analysis of a multidrug resistant strain with a drug-sensitive strain has also been performed \[[@CR32]\]. *In vitro* culture conditions may stress bacteria (*e.g.* due to exhaustion of static nutrients, build-up of toxic bacterial by-products and limited physical space). However, simulated *in vitro* environments do not accurately reflect the protein profile within the lung, because *A. baumannii* must adjust to the environment inside the host lung (*e.g.*, CO~2~ concentrations, temperature and immune system) to be able to cause pneumonia.

The goal of this study was to improve our knowledge of the pathogenesis and virulence of *A. baumannii* by considering how the bacterium adapts to its host. In order to obtain an overview of host-pathogen-interactions during *A. baumannii* infections, we used, for the first time, a proteomics approach to compare the *ex vivo* proteomes of *A. baumannii* grown under different that mimic the physiological conditions that bacteria must face during *in vivo* host infection.

Results {#Sec2}
=======

The objective of this study was to improve our knowledge of the pathogenesis and virulence of *A. baumannii* and to investigate how this *bacterium* adapts to its host. For this purpose, *A. baumannii* cells were cultured in LB (Luria-Bertani) medium with or without BALF (BALF model) and in Dulbecco's Modified Eagle's Medium (DMEM) medium with or without RAW 264.7 cells (macrophage model). The proteome composition of the *A. baumannii* cells in both models was analyzed in parallel, by using iTRAQ labelling and LC-MALDI-TOF/TOF to investigate the response of *A. baumannii* to exposure to macrophages/BALF (according to the scheme shown in Additional file [1](#MOESM1){ref-type="media"}).

*Acinetobacter baumannii* caused consolidated pneumonia {#Sec3}
-------------------------------------------------------

BALF contains lipids, nucleic acids, secretomes of macrophages, lymphocytes, neutrophils, eosinophils, epithelial cells, pneumocytes, monocytes and basophils. Moreover, infection is capable of causing changes in concentrations, ratios and numbers of proteins detected in BALF. Therefore, to simulate conditions in the respiratory tract in response to *A. baumannii* infection, rats were inoculated with the bacterium and BALFs were obtained 21 h later. For histological assessment of *A. baumannii* infection of the airway, lung specimens were stained with haematoxylin and eosin and examined microscopically. Abscess formation, with extensive infiltration of polymorphonuclear leukocytes was noted \[see Additional file [2](#MOESM2){ref-type="media"}\].

Quantitative (iTRAQ) data analysis {#Sec4}
----------------------------------

In the BALF model, *A. baumannii* was incubated simultaneously in LB and in LB supplemented with BALF (containing host soluble components present inside the lung 21 h after inoculation with *A. baumannii*) for 21 h at 37 °C and 5 % CO~2~ without shaking, in order to study the *A. baumannii* responses to soluble BALF components at the protein level by iTRAQ labelling and LC-MALDI/TOF analysis. Changes in the proteome of *A. baumannii* in response to soluble BALF components were examined. The rate of false positive results was estimated to be less than 1 % (with a confidence interval of 95 %) as the search was conducted in parallel with a decoy database using the "PSPEP on" mode, suggesting a high degree of confidence in the reported protein identifications. To evaluate the reproducibility and effectiveness of the iTRAQ experiments, we compared the proteins identified in each iTRAQ set. Overall, 8,310 unique peptides and 896 distinct proteins were detected with more than 95 % confidence in both iTRAQ sets. In biological replicate one, 730 proteins were identified and in biological replicate two, 853 proteins were identified. Only about 15.7 % of the proteins were identified with a single peptide. In total, 687 proteins (76.7 %) were identified in both biological replicates, and only 209 proteins (23.3 %) were unique for a single iTRAQ experiment. These results indicate the reliability of the iTRAQ identification of 687 proteins in all data sets. Compared with the control group, 111 identified proteins displayed significant changes in expression. In total, 50 proteins tended to be over-expressed (fold change \>1.5, p \<0.05) and 61 proteins tended to be under-expressed (fold change \<0.5, p \<0.05) relative to the control group (Table [1](#Tab1){ref-type="table"}).Table 1Differentially expressed proteins under ex vivo conditions in BALF modelProtein descriptionAbH12O-A2 locusSec.^a^BALF model/control^b^BALF model/control *p*-value^c^Pathogenesis and virulenceMolecular chaperone DnaKAIS05048.1NO1.77 (0.65)0.027Clp protease ClpXAIS05265.1NO1.51 (0.61)0.024Amino acid ABC transporter substrate-binding protein (NfuA-like)AIS05727.1YES2.38 (1.76)0.031Enoyl-CoA hydratase (PaaZ)AIS06043.1NO0.30 (0.11)0.012Peptidase M16AIS06751.1NO0.29 (0.16)0.007Aminopeptidase NAIS06953.1NO0.39 (0.21)0.023Protein CsuCAIS07073.1YES2.19 (0.76)0.003Protein CsuAAIS07075.1YES1.87 (0.95)0.036Membrane protein (OmpA)AIS07737.1YES1.51 (0.65)0.015Oligopeptidase AAIS07885.1NO0.48 (0.11)0.001ABC transporter ATP-binding protein (YjjK)AIS08062.1NO1.74 (0.61)0.038Amino acid metabolism and transportAspartate-semialdehyde dehydrogenaseAIS05215.1NO0.25 (0.19)0.0382-Isopropylmalate synthaseAIS05260.1NO0.31 (0.11)0.034Ketol-acid reductoisomeraseAIS05310.1NO0.31 (0.05)0.027Ornithine carbamoyltransferaseAIS06867.1NO0.40 (0.17)0.044Aspartate aminotransferaseAIS07065.1NO0.08 (0.07)0.000Glutamate synthaseAIS08029.1NO0.39 (0.20)0.025Carbohydrate metabolism and transportPhosphoglyceromutaseAIS05033.1NO0.26 (0.14)0.020Phosphoenolpyruvate synthaseAIS07024.1NO0.19 (0.04)0.000Glucose dehydrogenaseAIS07744.1NO0.19 (0.13)0.009Cell cycle control and mitosisCell division inhibitor MinDAIS05622.1NO1.63 (1.55)0.000tRNA uridine 5-carboxymethylaminomethyl modification proteinAIS07041.1NO2.70 (1.89)0.025Cell division protein FtsZAIS08195.1NO4.61 (1.68)0.001Cell wall/membrane/envelope biogenesisMembrane protein(OmpW)AIS05087.1YES2.25 (0.89)0.032UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA)AIS05387.1NO2.27 (1.47)0.002UDP-N-acetylmuramate-alanine ligase (MurC)AIS08199.1NO99.08 (0.00)0.020Coenzyme metabolismCoproporphyrinogen III oxidaseAIS07950.1NO0.31 (0.13)0.0043-Phosphoglycerate dehydrogenaseAIS07996.1NO0.38 (0.09)0.016Defense mechanisms (cellular processes and signaling)RND transporterAIS04803.1YES0.30 (0.22)0.004Energy production and conversionMalate dehydrogenaseAIS04961.1NO0.45 (0.23)0.038Inorganic pyrophosphataseAIS05013.1YES2.83 (1.43)0.030Aconitate hydrataseAIS05319.1NO0.21 (0.16)0.000NAD(P) transhydrogenase subunit alphaAIS05328.1NO2.49 (1.37)0.041NADH dehydrogenaseAIS05456.1NO0.44 (0.17)0.012Cytochrome C oxidase subunit IIAIS07026.1NO0.21 (0.23)0.016Malic enzymeAIS07199.1NO0.46 (0.10)0.041Isocitrate dehydrogenaseAIS07371.1NO0.29 (0.05)0.004Phosphoenolpyruvate carboxykinaseAIS07529.1NO2.23 (0.66)0.000Succinyl-CoA synthetase subunit betaAIS07559.1NO0.41 (0.06)0.035Energy production and conversion2-Oxoglutarate dehydrogenaseAIS07562.1NO0.20 (0.04)0.000Succinate dehydrogenaseAIS07563.1NO1.98 (0.64)0.017Type II citrate synthaseAIS07567.1NO0.22 (0.05)0.002OxidoreductaseAIS07724.1NO0.31 (0.22)0.001Malate dehydrogenaseAIS07865.1NO0.47 (0.06)0.040Acetyl-CoA hydrolaseAIS08069.1NO2.05 (0.67)0.008Pyruvate dehydrogenaseAIS08191.1NO0.36 (0.06)0.000Unknown functionHypothetical proteinAIS05481.1YES0.07 (0.10)0.013Peptidoglycan-binding protein LysMAIS05521.1YES0.05 (0.03)0.003Hypothetical proteinAIS06125.1YES0.17 (0.07)0.027DNA-binding proteinAIS07086.1YES0.08 (0.07)0.006PeptidaseAIS07285.1YES4.57 (3.14)0.000GlyoxalaseAIS07740.1YES0.39 (0.45)0.015Hypothetical proteinAIS07742.1YES1.84 (1.06)0.048General functional prediction only (typically, prediction of biochemical activity)Alpha/beta hydrolaseAIS06658.1YES0.09 (0.07)0.001GTPase obgAIS07390.1NO2.58 (1.05)0.025Hypothetical proteinAIS07569.1NO3.47 (1.83)0.027Inorganic ion transport and metabolismBacterioferritinAIS05502.1NO0.25 (0.18)0.013HydroperoxidaseAIS06129.1YES0.26 (0.10)0.000Inorganic ion transport and metabolismSuperoxide dismutaseAIS07203.1YES0.49 (0.14)0.013SulfurtransferaseAIS07821.1NO0.37 (0.28)0.006Intracellular trafficking and secretionRNA-binding proteinAIS05494.1NO2.07 (0.97)0.001Lipid metabolism3-Ketoacyl-CoA thiolaseAIS05097.1NO0.35 (0.18)0.049Multifunctional fatty acid oxidation complex subunit alphaAIS05098.1NO0.29 (0.08)0.000Acetyl-CoA carboxylaseAIS05368.1NO2.01 (0.67)0.0003-Hydroxyacyl-CoA dehydrogenaseAIS06051.1NO0.32 (0.22)0.023Beta-ketoadipyl CoA thiolaseAIS06052.1NO0.28 (0.10)0.0003-Methylcrotonyl-CoA carboxylaseAIS06111.1NO0.11 (0.04)0.002Short-chain dehydrogenaseAIS06130.1YES0.04 (0.05)0.040Acetyl-CoA acetyltransferaseAIS06469.1YES0.09 (0.13)0.027Acetyl-CoA carboxylaseAIS06900.1NO0.42 (0.17)0.0013-Hydroxy-2-methylbutyryl-CoA dehydrogenaseAIS07009.1NO0.25 (0.18)0.031Acetyl-CoA acetyltransferaseAIS07739.1YES0.24 (0.26)0.017Acyl-CoA dehydrogenaseAIS07780.1NO0.22 (0.16)0.000Nucleotide metabolism and transportGMP synthaseAIS04952.1NO0.31 (0.17)0.000Formyltetrahydrofolate deformylaseAIS05238.1NO1.64 (1.02)0.012Deoxyuridine 5′-triphosphate nucleotidohydrolaseAIS05628.1NO4.45 (6.37)0.039DihydroorotaseAIS05812.1NO1.79 (1.15)0.043Nucleotide metabolism and transportOrotate phosphoribosyltransferaseAIS08207.1NO2.73 (1.78)0.004Post-translational modification, protein turnover, chaperone functionsPeroxidaseAIS07758.1YES0.25 (0.21)0.033Replication and repairChromosomal replication initiation proteinAIS04811.1NO81.66 (31.26)0.017DNA gyrase subunit AAIS07481.1NO0.09 (0.16)0.004TranscriptionAntitermination protein NusGAIS05075.1NO2.00 (0.81)0.010DNA-directed RNA polymerase subunit betaAIS05080.1NO0.26 (0.05)0.000DNA-directed RNA polymerase subunit beta'AIS05081.1NO0.10 (0.04)0.000RNA polymerase sigma factor RpoDAIS07572.1NO1.92 (1.40)0.042TranslationIsoleucine-tRNA ligaseAIS04850.1NO0.28 (0.09)0.001Arginine-tRNA ligaseAIS04960.1NO0.47 (0.16)0.01950S ribosomal protein L1AIS05077.1YES3.40 (0.93)0.00030S ribosomal protein S15AIS05149.1NO15.56 (6.87)0.04550S ribosomal protein L28AIS05235.1YES1.85 (0.68)0.042Leucyl-tRNA synthetaseAIS05306.1NO0.39 (0.16)0.029Threonyl-tRNA synthetaseAIS05352.1NO0.09 (0.16)0.00030S ribosomal protein S7AIS05609.1NO9.91 (4.58)0.000Elongation factor TuAIS05611.1NO0.34 (0.05)0.002Cysteinyl-tRNA synthetaseAIS05938.1NO0.18 (0.11)0.01530S ribosomal protein S6AIS07031.1NO3.56 (0.80)0.004Translation50S ribosomal protein L9AIS07033.1NO4.70 (2.06)0.00030S ribosomal protein S21AIS07108.1YES4.33 (3.26)0.04050S ribosomal protein L21AIS07586.1NO4.45 (2.38)0.029Valyl-tRNA synthetaseAIS07599.1NO0.17 (0.14)0.00030S ribosomal protein S9AIS07845.1YES6.19 (2.19)0.00550S ribosomal protein L17AIS07895.1YES15.14 (7.44)0.02530S ribosomal protein S11AIS07898.1YES3.40 (1.58)0.00250S ribosomal protein L15AIS07902.1NO5.06 (1.54)0.00050S ribosomal protein L6AIS07906.1YES5.35 (2.12)0.00030S ribosomal protein S8AIS07907.1YES7.52 (1.56)0.00750S ribosomal protein L5AIS07909.1NO7.18 (2.38)0.00050S ribosomal protein L14AIS07911.1NO5.20 (1.87)0.00250S ribosomal protein L22AIS07916.1NO2.03 (0.76)0.01250S ribosomal protein L23AIS07919.1YES1.77 (0.58)0.043Aminoglycoside phosphotransferaseAIS08113.1NO2.88 (4.81)0.015The protein profiles produced by *A. baumannii* grown in modified BALF were performed using iTRAQ reagents and LC-MS/MS. Differential expression was defined by a relative abundance ratio \>1.5 and \<0.5^a^Secretion prediction are based on (SignalP 4.1 (<http://www.cbs.dtu.dk/services/SignalP/>), Phobius (<http://phobius.sbc.su.se/>), PrediSi (<http://www.predisi.de/>), TatP 1.0 ([www.cbs.dtu.dk/services/TatP-1.0](http://www.cbs.dtu.dk/services/TatP-1.0)), Tatfind 1.4 (<http://signalfind.org/tatfind.html>), SecretomeP 2.0 ([www.cbs.dtu.dk/services/SecretomeP](http://www.cbs.dtu.dk/services/SecretomeP)), TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>), DAS-TMfilter (<http://www.enzim.hu/DAS/DAS.html>), LipoP 1.0 ([www.cbs.dtu.dk/services/LipoP](http://www.cbs.dtu.dk/services/LipoP)), DOLOP (<http://www.mrc-lmb.cam.ac.uk/genomes/dolop/>), and LIPO (<http://services.cbu.uib.no/tools/lipo>))^b^Average relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).^c^Determined by Student's *t* test. Values of less than 0.05 are considered significant

In the macrophage model, infection of macrophages was induced with *A. baumannii* (multiplicity of infection 3). Control and infected cells were incubated simultaneously for 21 h at 37 °C and 5 % CO~2,~ without shaking, in order to study the *A. baumannii* responses to immune system cells at the protein level by iTRAQ labelling and LC-MALDI/TOF analysis. Changes in the proteome of *A. baumannii* in response to RAW 264.7 cells were also examined. In comparison with the control group, 97 identified proteins displayed significant changes in expression. A total of 76 proteins displayed increased expression levels (fold change \>1.5, p \<0.05) and 21 proteins displayed decreased expression levels (fold change \<0.5, p \<0.05) relative to the control group (Table [2](#Tab2){ref-type="table"}).Table 2Differentially expressed proteins under ex vivo conditions in macrophage modelProtein descriptionAbH12O-A2 locusSec.^a^macrophage model/ control^b^macrophage model/ control *p*-value^c^Pathogenesis and virulenceNucleotidyl transferaseAIS04894.1NO2.83 (0.60)0.013Trigger factorAIS05263.1NO3.37 (0.37)0.016ATPase AAA (PaaA)AIS06044.1NO5.50 (4.44)0.028Siderophore achromobactin biosynthesis proteína AcsCAIS06377.1NO0.44 (0.17)0.000Cyclophilin (PPIase)AIS06968.1NO2.83 (0.87)0.041Protein CsuCAIS07073.1YES0.16 (0.06)0.004Protein CsuAAIS07075.1YES0.31 (0.22)0.040MetallopeptidaseAIS07555.1YES0.20 (0.16)0.028Membrane protein (OmpA)AIS07737.1YES7.80 (2.78)0.049Oligopeptidase AAIS07885.1NO4.83 (0.88)0.006ABC transporter ATP-binding protein (YjjK)AIS08062.1NO2.33 (0.77)0.046Amino acid metabolism and transportAspartate aminotransferaseAIS07065.1NO0.39 (0.18)0.010Serine hydroxymethyltransferaseAIS07167.1NO2.54 (0.44)0.043Carbamoyl-phosphate synthaseAIS07544.1NO2.75 (1.74)0.0354-Hydroxyphenylpyruvate dioxygenaseAIS08279.1NO4.74 (1.15)0.000Carbohydrate metabolism and transportPhosphoglyceromutaseAIS05033.1NO3.94 (1.06)0.032Glyceraldehyde-3-phosphate dehydrogenaseAIS07393.1NO3.08 (0.66)0.016Cell cycle control and mitosisCell division protein FtsAAIS08196.1NO4.74 (7.32)0.002Cell wall/membrane/envelope biogenesisMembrane proteinAIS06856.1YES8.02 (7.90)0.006RacemaseAIS07059.1NO0.20 (0.13)0.037UDP-N-acetylmuramate-alanine ligase (MurC)AIS08199.1NO8.17 (3.95)0.040Coenzyme metabolismPantoate-beta-alanine ligase (PanC)AIS05347.1NO6.08 (8.59)0.0103-Phosphoglycerate dehydrogenaseAIS07996.1NO3.77 (0.88)0.014Defense mechanisms (cellular processes and signaling)Beta-lactamaseAIS07280.1YES2.09 (0.41)0.049ABC transporterAIS07290.1NO0.39 (0.18)0.037Energy production and conversionATP synthase subunit BAIS04971.1NO5.50 (2.54)0.044ATP synthase F0F1 subunit betaAIS04975.1NO3.63 (0.48)0.002Bifunctional aconitate hydratase 2/2-methylisocitrate dehydrataseAIS06989.1NO3.16 (0.31)0.002Isocitrate dehydrogenaseAIS07371.1NO4.57 (0.55)0.002Electron transfer flavoprotein subunit betaAIS07482.1YES5.65 (0.89)0.005Dihydrolipoamide succinyltransferaseAIS07561.1NO2.44 (0.45)0.036Fumarate reductaseAIS07564.1NO3.08 (0.59)0.010Acetyl-CoA hydrolaseAIS08069.1NO4.74 (1.68)0.040NADPH:quinone oxidoreductaseAIS08156.1NO15.42 (16.20)0.034Dihydrolipoamide acetyltransferaseAIS08190.1YES3.08 (0.73)0.010Unknown functionHypothetical proteinAIS05430.1NO19.23 (19.19)0.001Hypothetical proteinAIS05481.1YES0.17 (0.08)0.000Unknown functionHypothetical proteinAIS05936.1YES0.23 (0.13)0.006DNA-binding proteinAIS07086.1YES0.24 (0.17)0.037Hypothetical proteinAIS07091.1NO0.21 (0.12)0.000DcaP-like proteinAIS07608.1YES11.07 (6.85)0.023GlyoxalaseAIS07740.1YES0.30 (0.23)0.036Hypothetical proteinAIS07873.1YES0.42 (0.16)0.011Inorganic ion transport and metabolismHydroperoxidaseAIS06129.1YES0.35 (0.13)0.008ABC transporter permeaseAIS07421.1YES8.17 (3.60)0.034Lipid metabolism3-Oxoacyl-ACP reductaseAIS05519.1YES2.68 (0.94)0.038Enoyl-CoA hydrataseAIS06112.1NO0.17 (0.24)0.004Short-chain dehydrogenaseAIS06130.1YES0.10 (0.07)0.032Nucleotide metabolism and transportN5-carboxyaminoimidazole ribonucleotide mutaseAIS04832.1NO4.02 (2.98)0.010Ribose-phosphate pyrophosphokinaseAIS05530.1NO4.61 (2.76)0.000Deoxyuridine 5′-triphosphate nucleotidohydrolaseAIS05628.1NO0.28 (0.32)0.032Orotidine 5′-phosphate decarboxylaseAIS06325.1NO0.19 (0.21)0.032Adenylosuccinate lyaseAIS07333.1NO6.31 (2.68)0.047Xanthine phosphoribosyltransferaseAIS07874.1NO2.42 (0.69)0.048Inosine-5-monophosphate dehydrogenaseAIS08184.1NO3.94 (0.81)0.006Post-translational modification, protein turnover, chaperone functionsMolecular chaperone DnaKAIS04838.1NO2.13 (0.15)0.000Post-translational modification, protein turnover, chaperone functionsOsmotically inducible protein CAIS04957.1NO3.16 (1.14)0.029Replication and repairDNA repair proteinAIS04967.1YES3.87 (1.19)0.033DNA polymerase IAIS05372.1NO0.31 (0.34)0.038Secondary metabolites: biosynthesis, transport and catabolismmRNA 3′-end processing factorAIS06680.1NO0.10 (0.19)0.027TranscriptionDNA-directed RNA polymerase subunit beta'AIS05081.1NO2.86 (0.42)0.025Transcription elongation factor NusAAIS05126.1NO3.53 (0.94)0.036Transcription termination factor RhoAIS05365.1NO3.60 (1.54)0.025DNA-binding proteinAIS07045.1NO9.73 (6.82)0.029DNA-directed RNA polymerase subunit alphaAIS07896.1NO3.28 (0.46)0.001TranslationTyrosyl-tRNA synthetaseAIS04798.1NO3.37 (0.97)0.00923S rRNA methyltransferaseAIS05117.1NO3.37 (4.80)0.037Alanyl-tRNA synthetaseAIS05862.1NO3.05 (1.16)0.00430S ribosomal protein S20AIS06347.1YES3.77 (2.31)0.026Ribosome-recycling factorAIS06861.1NO3.91 (1.42)0.045Peptide chain release factor 1AIS07012.1NO0.34 (0.27)0.02130S ribosomal protein S6AIS07031.1NO6.92 (1.66)0.00030S ribosomal protein S18AIS07032.1NO22.70 (16.56)0.02850S ribosomal protein L9AIS07033.1NO8.17 (3.02)0.00230S ribosomal protein S2AIS07184.1NO3.87 (1.07)0.040TranslationTryptophanyl-tRNA synthetaseAIS07557.1NO8.09 (4.24)0.02350S ribosomal protein L27AIS07585.1YES10.28 (8.73)0.027Aspartyl-tRNA synthetaseAIS07787.1NO5.92 (1.79)0.03830S ribosomal protein S9AIS07845.1YES5.86 (1.38)0.00950S ribosomal protein L17AIS07895.1YES9.64 (4.81)0.00330S ribosomal protein S4AIS07897.1NO13.30 (3.19)0.01050S ribosomal protein L15AIS07902.1NO5.92 (1.17)0.00030S ribosomal protein S5AIS07904.1YES4.61 (5.00)0.00350S ribosomal protein L18AIS07905.1YES9.04 (10.58)0.03350S ribosomal protein L6AIS07906.1YES7.59 (1.58)0.03730S ribosomal protein S8AIS07907.1YES10.76 (2.98)0.01150S ribosomal protein L5AIS07909.1NO7.73 (2.20)0.00050S ribosomal protein L24AIS07910.1YES4.25 (0.70)0.03850S ribosomal protein L14AIS07911.1NO11.07 (12.57)0.00230S ribosomal protein S17AIS07912.1NO12.36 (3.91)0.04850S ribosomal protein L16AIS07914.1YES29.11 (22.95)0.03830S ribosomal protein S3AIS07915.1NO6.73 (3.82)0.02650S ribosomal protein L22AIS07916.1NO1.89 (0.85)0.03550S ribosomal protein L2AIS07918.1YES7.87 (3.98)0.03850S ribosomal protein L23AIS07919.1YES4.45 (1.04)0.01850S ribosomal protein L4AIS07920.1NO14.45 (7.02)0.002Translation50S ribosomal protein L3AIS07921.1NO6.25 (1.29)0.042The protein profiles produced by *A. baumannii* grown in the presence of macrophages were performed using iTRAQ reagents and LC-MS/MS. Differential expression was defined by a relative abundance ratio \>1.5 and \<0.5^a^Secretion prediction are based on (SignalP 4.1 (<http://www.cbs.dtu.dk/services/SignalP/>), Phobius (<http://phobius.sbc.su.se/>), PrediSi (<http://www.predisi.de/>), TatP 1.0 ([www.cbs.dtu.dk/services/TatP-1.0](http://www.cbs.dtu.dk/services/TatP-1.0)), Tatfind 1.4 (<http://signalfind.org/tatfind.html>), SecretomeP 2.0 ([www.cbs.dtu.dk/services/SecretomeP](http://www.cbs.dtu.dk/services/SecretomeP)), TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>), DAS-TMfilter (<http://www.enzim.hu/DAS/DAS.html>), LipoP 1.0 ([www.cbs.dtu.dk/services/LipoP](http://www.cbs.dtu.dk/services/LipoP)), DOLOP (<http://www.mrc-lmb.cam.ac.uk/genomes/dolop/>), and LIPO (<http://services.cbu.uib.no/tools/lipo>))^b^Average relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).^c^Determined by Student's *t* test. Values of less than 0.05 are considered significant

Overall, 179 differentially expressed proteins were identified in both models. 111 proteins were modulated in the BALF model and 97 proteins were modulated in the macrophage model. In the BALF model, 45.0 % of the differentially expressed proteins were over-expressed. In the macrophage model, 78.4 % of the modulated proteins were over-expressed. Of the 179 modulated proteins, 16.2 % (29 proteins) were differentially expressed in both models, 51.7 % (15 proteins) were overexpressed, 20.7 % (6 proteins) were underexpressed and 27.6 % (8 proteins) were opposite (over-expressed in a model and under-expressed in the other model) (Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}).Fig. 1Venn diagram showing the number and relationship between *A. baumannii* proteins that were differentially expressed in comparison of 2 ex vivo models. Circles represent the set of over-expressed proteins (red) and under-expressed proteins (dark blue) in the macrophage model and the set of over-expressed proteins (yellow) and under-expressed proteins (light blue) in the BALF model. The number of proteins differentially expressed is indicated in each set or subsetTable 3Differentially expressed proteins in both ex vivo modelsProtein descriptionAbH12O-A2 locusSec.^a^BALF model/control^b^BALF model/control *p*-value^c^macrophage model/control^b^macrophage model/control *p*-value^c^Pathogenesis and virulenceProtein CsuCAIS07073.1YES2.19 (0.76)0.0030.16 (0.06)0.004Protein CsuAAIS07075.1YES1.87 (0.95)0.0360.31 (0.22)0.040Membrane protein (OmpA)AIS07737.1YES1.51 (0.65)0.0157.80 (2.78)0.049Oligopeptidase AAIS07885.1NO0.48 (0.11)0.0014.83 (0.88)0.006ABC transporter ATP-binding protein (YjjK)AIS08062.1NO1.74 (0.61)0.0382.33 (0.77)0.046Amino acid metabolism and transportAspartate aminotransferaseAIS07065.1NO0.08 (0.07)0.0000.39 (0.18)0.010Carbohydrate metabolism and transportPhosphoglyceromutaseAIS05033.1NO0.26 (0.14)0.0203.94 (1.06)0.032Cell wall/membrane/envelope biogenesisUDP-N-acetylmuramate-alanine ligase (MurC)AIS08199.1NO99.08 (0.00)0.0208.17 (3.95)0.040Coenzyme metabolism3-Phosphoglycerate dehydrogenaseAIS07996.1NO0.38 (0.09)0.0163.77 (0.88)0.014Energy production and conversionIsocitrate dehydrogenaseAIS07371.1NO0.29 (0.05)0.0044.57 (0.55)0.002Acetyl-CoA hydrolaseAIS08069.1NO2.05 (0.67)0.0084.74 (1.68)0.040Unknown functionHypothetical proteinAIS05481.1YES0.07 (0.10)0.0130.17 (0.08)0.000DNA-binding proteinAIS07086.1YES0.08 (0.07)0.0060.24 (0.17)0.037GlyoxalaseAIS07740.1YES0.39 (0.45)0.0150.30 (0.23)0.036Inorganic ion transport and metabolismHydroperoxidaseAIS06129.1YES0.26 (0.10)0.0000.35 (0.13)0.008Lipid metabolismShort-chain dehydrogenaseAIS06130.1YES0.04 (0.05)0.0400.10 (0.07)0.032Nucleotide metabolism and transportDeoxyuridine 5′-triphosphate nucleotidohydrolaseAIS05628.1NO4.45 (6.37)0.0390.28 (0.32)0.032TranscriptionDNA-directed RNA polymerase subunit beta'AIS05081.1NO0.10 (0.04)0.0002.86 (0.42)0.025Translation30S ribosomal protein S6AIS07031.1NO3.56 (0.80)0.0046.92 (1.66)0.00050S ribosomal protein L9AIS07033.1NO4.70 (2.06)0.0008.17 (3.02)0.00230S ribosomal protein S9AIS07845.1YES6.19 (2.19)0.0055.86 (1.38)0.00950S ribosomal protein L17AIS07895.1YES15.14 (7.44)0.0259.64 (4.81)0.00350S ribosomal protein L15AIS07902.1NO5.06 (1.54)0.0005.92 (1.17)0.00050S ribosomal protein L6AIS07906.1YES5.35 (2.12)0.0007.59 (1.58)0.03730S ribosomal protein S8AIS07907.1YES7.52 (1.56)0.00710.76 (2.98)0.01150S ribosomal protein L5AIS07909.1NO7.18 (2.38)0.0007.73 (2.20)0.00050S ribosomal protein L14AIS07911.1NO5.20 (1.87)0.00211.07 (12.57)0.00250S ribosomal protein L22AIS07916.1NO2.03 (0.76)0.0121.89 (0.85)0.03550S ribosomal protein L23AIS07919.1YES1.77 (0.58)0.0434.45 (1.04)0.018The protein profiles produced by *A. baumannii* grown in modified BALF and in the presence of macrophages were performed using iTRAQ reagents and LC-MS/MS. Differential expression was defined by a relative abundance ratio \>1.5 and \<0.5^a^Secretion prediction are based on (SignalP 4.1 (<http://www.cbs.dtu.dk/services/SignalP/>), Phobius (<http://phobius.sbc.su.se/>), PrediSi (<http://www.predisi.de/>), TatP 1.0 ([www.cbs.dtu.dk/services/TatP-1.0](http://www.cbs.dtu.dk/services/TatP-1.0)), Tatfind 1.4 (<http://signalfind.org/tatfind.html>), SecretomeP 2.0 ([www.cbs.dtu.dk/services/SecretomeP](http://www.cbs.dtu.dk/services/SecretomeP)), TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>), DAS-TMfilter (<http://www.enzim.hu/DAS/DAS.html>), LipoP 1.0 ([www.cbs.dtu.dk/services/LipoP](http://www.cbs.dtu.dk/services/LipoP)), DOLOP (<http://www.mrc-lmb.cam.ac.uk/genomes/dolop/>), and LIPO (<http://services.cbu.uib.no/tools/lipo>))^b^Average relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).^c^Determined by Student's *t* test. Values of less than 0.05 are considered significant

Analysis of modulated proteins {#Sec5}
------------------------------

According to their predicted biological functions, the differentially expressed proteins were divided into 19 groups (Fig. [2](#Fig2){ref-type="fig"}). The largest groups consisted of proteins involved in translation (58), followed by the proteins involved in energy production and conversion (27) and by proteins involved in pathogenesis and virulence (23). Most of the proteins over-expressed in the BALF model were involved in translation (38.0 %), followed by pathogenesis and virulence (14.0 %), and energy production and conversion (10.0 %). In the macrophage model, most were involved in translation (40.8 %), followed by energy production and conversion (13.2 %), and pathogenesis and virulence (10.5 %). Most of the proteins that were under-expressed in the BALF model were involved in energy production and conversion (19.7 %) and in the macrophage model most were proteins of unknown function (28.6 %).Fig. 2Distribution of differentially expressed proteins in *A. baumannii* following ex vivo incubation according to functional categories. The stacked bar chart shows the number of over-expressed proteins (red) and under-expressed proteins (dark blue) in the macrophage model and the number of over-expressed proteins (yellow) and under-expressed proteins (light blue) in the BALF model in each functional category

Of the 29 proteins differentially expressed in both models, most were involved in translation (37.9 %), followed by pathogenesis and virulence (17.2 %) and by unknown function (10.3 %). Most of the over-expressed proteins were involved in translation, whereas most of the under-expressed proteins were proteins of unknown function, and 50.0 % of opposite proteins were associated with metabolism (Table [3](#Tab3){ref-type="table"}).

RT-PCR {#Sec6}
------

We selected some proteins for validation of the proteomic data by RT-PCR analysis. The candidate proteins, *NfuA*-like, *YjjK*, *CsuC*, *OmpW*, *OmpA*, *ClpX*, *DNA repair*, *PaaA* and *PpiA* were selected on the basis of their differential expression as representative of pathogenesis and virulence, cell wall/membrane/envelope biogenesis and other functional categories.

### BALF model {#Sec7}

RT-PCR analysis was applied to 6 genes coding for differentially expressed proteins to confirm the findings of the proteomic analysis. Expression of most, but not all, of these genes paralleled expression of the corresponding proteins revealed by proteomic analysis. Four (*NfuA*-like, *YjjK*, *CsuC* and *OmpW*) of the six selected genes were over-expressed at the transcriptional level in the sample relative to the control which is consistent with the results of protein expression. However, there was a slight inconsistency between the translational and transcriptional levels of *OmpA* and *ClpX*. Expression of *OmpA* and *ClpX* mRNA revealed similar patterns in the sample relative to the control, despite the increased levels of the respective mRNAs (Fig. [3](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}).Fig. 3RT-PCR analysis of different genes coding for differentially expressed proteins in controls and samples (BALF model). All expression results were normalized relative to *RpoB* by the 2^−ΔΔCt^ method. For all genes, relative mRNA expression is presented as a fold-change value relative to the control

### Macrophage model {#Sec8}

RT-PCR analysis of 7 genes coding for differentially expressed proteins was performed to confirm the results of the proteomic analysis. Expression of most, but not all, of the genes paralleled the expression of the corresponding proteins revealed by proteomic analysis. Five (*DNA repair*, *PaaA*, *PpiA*,*YjjK* and *OmpW*) of the seven selected genes were over-expressed at the transcriptional level in the sample, relative to the control, which is consistent with the results of protein expression. However, there was a slight inconsistency between the translational and transcriptional levels of *OmpA* and an inconsistency between the translational and transcriptional levels of *CsuC*. The mRNA expression of *OmpA* revealed similar patterns in the sample, relative to the control, despite the increased levels of the respective mRNAs. The mRNA expression of *CsuC* was 1.6 times higher and the protein abundance was more than six times lower in the sample than in the control (Fig. [4](#Fig4){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}), probably because of post-transcriptional regulation \[[@CR33]\].Fig. 4RT-PCR analysis of different genes coding for differentially expressed proteins in controls and samples (macrophage model). All expression results were normalized relative to *RpoB* by the 2^−ΔΔCt^ method. For all genes, relative mRNA expression is presented as a fold-change value relative to the control

Comparison of the results obtained by iTRAQ labelling-LC-MALDI/TOF and RT-PCR showed that the changes observed in protein abundance between samples of both *ex vivo* models and controls were also reflected in the mRNA levels.

Discussion {#Sec9}
==========

The host activated response to *Acinetobacter baumannii* is not well understood. Some studies have described changes in *A. baumannii* gene expression under *in vivo*-mimicking conditions. However, most of these studies focused on transcriptional changes of one or a few genes of interest, mostly under iron limiting conditions \[[@CR34]--[@CR38]\]. A microarray study defined the expression properties of *A. baumannii* during growth in human serum and demonstrated significant over-expression of iron acquisition systems, of genes associated with epithelial cell adherence, DNA uptake and of numerous putative drug efflux pumps \[[@CR39]\]. At the protein level, comparative analysis of total lysate and outer membrane fractions isolated from *A. baumannii* cultured under iron-rich and iron-chelated conditions led to identification of 58 modulated proteins \[[@CR40]\]. There remains an alarmingly large gap in our knowledge of the pathogenesis and nature of *A. baumannii* virulence. A better understanding of the adaptation of *A. baumannii* to the host and its molecular pathogenesis is essential for the development of new therapeutic and diagnostic methods. Research studies that address the *A. baumannii* proteome *in vivo* and the proteome that is produced in the presence of fluid or host cells are lacking. In contrast to the numerous proteomic studies of *A. baumannii* cultivated *in vitro* laboratory settings, only one microarray study has been carried out *ex vivo*, and no *ex vivo* or *in vivo* proteomic studies have been performed. This is because of technical limitations, which severely limit the number of recovered bacteria, and the potential contamination of sample preparations by host cell nucleic acids or proteins.

To identify putative pathogenesis and virulence factors that mediate *A. baumannii* pathogenesis, we used 2 *ex vivo* models and a quantitative proteomics approach. We provide evidence that expression of 179 *A. baumannii* proteins is affected by the host. Comparison of both models showed that 83 % of the proteins detected were grouped in the same category in both models (under-expressed, over-expressed and un-modulated) and that most of the proteins were unmodulated, which indicates that the host proteins may target and regulate a specific small group of *A. baumannii* proteins. The modulated proteins possess diverse functions (Fig. [2](#Fig2){ref-type="fig"}, Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}), which suggests a complex interaction between the bacterium and the host. Thus, in the BALF model, 50 of the proteins identified were over-expressed, whereas 61 were under-expressed. Some of these functional groups are clearly over-expressed for functioning in cell wall/membrane/envelope biogenesis, nucleotide metabolism and transport and cell cycle control and mitosis. Other important biological processes, such as pathogenesis and virulence and translation, were mainly over-expressed. However, other metabolic proteins involved in, *e.g.*, amino acid metabolism and lipid metabolism were under-expressed. In the macrophage model, 76 of the proteins identified were over-expressed, whereas 21 were under-expressed. Some of these functional groups are clearly over-expressed for functioning in translation, transcription and energy production and conversion. Other important biological processes, such as pathogenesis and virulence and nucleotide metabolism and transport, were mainly over-expressed. However, other functional groups involved in lipid metabolism were under-expressed. Although both models yielded generally similar results, some differences in the findings are not surprising, for the following reasons. First, different rodents species were used as hosts. Moreover, some of the major influencing factors identified in the BALF model include nutritional differences between samples (LB broth+lipids, nucleic acids, peptides and proteins) and controls (LB) and stress resulting from host inflammatory response (proteins important for immunity and host defence functions, such as surfactant protein A and surfactant protein D). However, in the macrophage model, these factors may compete with macrophages for available nutrients and stress resulting from interaction with a single host cell type.

Proteomic comparison of the levels of protein expression in the models revealed that 82 proteins were only modulated by BALF, 68 proteins were only modulated by macrophages and 29 proteins were modulated by both. Of these 29 proteins, 15 were over-expressed, 6 proteins were under-expressed and 8 proteins were opposite (Fig. [1](#Fig1){ref-type="fig"}). Interestingly, 50.0 % of opposite proteins were associated with metabolism (phosphoglyceromutase, 3-phosphoglycerate dehydrogenase, isocitrate dehydrogenase and deoxyuridine 5′-triphosphate nucleotidohydrolase). This is probably due to differences in the concentration of available nutrients in both models and to competition with macrophages for available nutrients in the macrophage model. Over-expressed amino acid catabolism was also observed in the macrophage model and under-expressed amino acid catabolism in the BALF model (Table [3](#Tab3){ref-type="table"}), indicating that amino acids constitute a major source of nitrogen for *A. baumannii* in the macrophage model. The availability of amino acids is probably also partly due to uptake of oligopeptides. Thus, the oligopeptidase A was over-expressed in the macrophage model and under-expressed in the BALF model. Moreover, CsuC and CsuA were over-expressed in the host cell-free model (the BALF model) and under-expressed in macrophage model, because these proteins are involved in initial attachment to abiotic surfaces but not in the mechanism of adherence to biotic surfaces. Nevertheless, the explanation is not as obvious in the case of the modulation of DNA-directed RNA polymerase subunit beta'.

In the macrophage model, 3 predicted outer membrane proteins were over-expressed (a DcaP-like protein, a membrane protein and OmpA -iTRAQ ratio between 7.80 and 11.07). In the BALF model, 2 predicted outer membrane proteins were over-expressed (OmpW family protein and OmpA -iTRAQ ratio between 1.51 and 2.25). In the macrophage model, 21 predicted secreted proteins were also over-expressed (average iTRAQ ratio 7.88) and 10 were under-expressed (average iTRAQ ratio 0.25). In the BALF model, 17 predicted secreted proteins were over-expressed (average iTRAQ ratio 4.03) and 13 were under-expressed (average iTRAQ ratio 0.20). The modifications that *A. baumannii* undergoes as a result of host-induced stress include changes in membrane and secretome composition; these changes were greater in the macrophage model than in the BALF model (host cell-free model) probably due to pathogen-host cell interactions. We conclude that the outer membrane and secretome are changed by the host cells and host secretome.

Interestingly, we found that the UDP-N-acetylmuramate-L-alanine ligase (MurC) protein was strongly over-expressed in both *ex vivo* models (iTRAQ ratio of 99.08 in the BALF model, and iTRAQ ratio of 8.17 in macrophage model). We also observed that UDP-N-acetylglucosamine 1-carboxyvinyl transferase (MurA) was over-expressed in the BALF model, but not significantly over-expressed in the macrophage model (p \> 0.05). In peptidoglycan synthesis, uridine-diphospho-*N*-acetylglucosamine is converted via MurA and MurB to UDP--*N*-acetylmuramic acid, to which alanine is added by MurC. These are essential steps in cell wall biosynthesis in bacteria \[[@CR41], [@CR42]\]. Moreover, MurA is required for full virulence in *Listeria monocytogenes* \[[@CR43]\]. In this context, MurA has previously been suggested as a potential drug target, and effective inhibitors of this protein have been identified \[[@CR44]\]. Detection of MurC polypeptides in humans could provide a method for diagnosis and/or prognosis of an infection. Levels of MurC polypeptides could be determined using assay techniques such as include antibody detection, ELISA assays, antibody sandwich assays and Western Blot analysis. Monoclonal antibodies against *A. baumannii* MurC similar to those generated by Zoeiby *et al.* could be used to detect MurC polypeptides. Zoeiby *et al.* used purified *P. aeruginosa* MurC protein to develop monoclonal antibodies against MurC. Moreover, Zoeiby *et al.* suggested that a specific inhibitor designed against *P. aeruginosa* MurC may display universal activity against all bacteria \[[@CR45]\]. However, other authors have observed that C-1, a competitive inhibitor of ATP binding to the MurC enzyme, was equally effective at inhibiting MurC from *E. coli, Klebsiella pneumoniae and Proteus mirabilis*, but that MurC enzymes from more distantly related Gram-negative species such as *Acinetobacter baylyi, Pseudomonas aeruginosa and Haemophilus influenzae* were not inhibited \[[@CR46]\]. More recently, MurC enzymes from *Escherichia coli and Pseudomonas aeruginosa* have been found to be inhibited by a novel class of pyrazolopyrimidines \[[@CR47]\].

Putative virulence-associated factors {#Sec10}
-------------------------------------

Several putative virulence factors were modulated in both *ex vivo* models. Blast analysis (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) \[[@CR48], [@CR49]\] revealed significant alignment between the nucleotidyl transferase (AIS04894.1), which was found to be over-expressed in the macrophage model (but not significantly modulated (p \> 0.05) in the BALF model) and UTP-glucose-1-phosphate uridylyltransferase (GalU) (query cover 100 % and Evalue = 0.0). The *GalU* gene encodes for production of UTP-glucose-1-phosphate uridyltransferase, an enzyme that catalyzes the formation of UDP-glucose and is known to have a key role in biosynthesis of cell-envelope-associated carbohydrates (*e.g.* lipopolysaccharides \[LPS\] and capsule) in a variety of bacterial species. In many Gram-negative pathogens, mutations in *GalU* lead to attenuated virulence, mainly because of changes in LPS or capsular structures. Formation of these polysaccharides is critical to bacterial virulence because this enables the bacteria to evade attack by the host immune system. The *GalU* gene has also been found to be important for pathogenesis of *e.g. Pseudomonas aeruginosa* and *Francisella tularensis* \[[@CR50]--[@CR54]\].

Bacteria and their hosts are involved in competition for available iron. In the host, iron is sequestered by ferritin, transferrin, haemoglobin, myoglobin, haptoglobin and haemopexin, thus decreasing the availability of free iron to concentrations below those needed for bacteria to persist in the environment. Therefore, bacteria must survive by competing with the host for iron through the expression of iron acquisition systems. These systems produce high affinity iron chelators known as siderophores, which are secreted into the extracellular milieu \[[@CR55], [@CR56]\]. Lipocalin-1 is secreted by the lingual glands, sweat glands, prostate, and secretory glands of the tracheobronchial tract, as well as by the nasal mucosa into BALF, sweat, saliva, tear, sputum and nasal fluids. Lipocalin-2, which is secreted by neutrophils, macrophages, dendritic cells and exocrine glands into trachea, lung, sputum, BAL, stomach, small intestine, pancreas, kidney, prostate, thymus and plasma, interferes with siderophore-mediated iron-uptake. Lipocalin-1 binds to different bacterial siderophores, including bacterial catecholate-type (enterobactin) and hydroxamate-type (ferricrocin) and mixed citrate-hydroxamates (aerobactin). Lipocalin-2 binds to different bacterial siderophores, including enterobactin-type bacterial siderophores and carboxy-mycobactins. To defend themselves against the host, some bacteria use countermeasures to subvert the iron-withholding effects of Lipocalin-2. For example, *Salmonella* and *Klebsiella* spp. glycosylate enterobactin, whereas *M. tuberculosis* modifies its carboxymycobactins. Both mechanisms sterically impair the ability of Lipocalin-2 to bind these siderophores \[[@CR57]--[@CR60]\]. NfuA-like has multiple functional roles related to iron-mediated stress. NfuA-like is involved in intracellular iron metabolism and, as demonstrated in an infection model, it also plays a role in the virulence of *A. baumannii* by protecting infecting bacteria from oxidative responses rather than providing iron to bacteria grown under iron---limited conditions imposed by cultured human alveolar epithelial cells and *G. mellonella* larvae \[[@CR37]\]. In the present study, we observed that in both models, proteins involved in biosynthesis of the siderophore aerobactin were not significantly modulated (p \> 0.05), probably because lipocalin-1 binds to aerobactin. We also observed that one of the under-expressed proteins (not significantly under-expressed (p \> 0.05) in the BALF model) is associated with biosynthesis of the siderophore achromobactin (AIS06377.1). This may be because although achromobactin is an efficient hydroxycarboxylate siderophore at low pH (pH \< 5), achromobactin could not compete with stronger siderophores such as catecholates at physiological pH \[[@CR59]\]. In both models, NfuA-like was also over-expressed (although not significantly (p \> 0.05), in the macrophage model). Altogether, these results suggest a third system for iron acquisition in *A. baumannii* strain AbH12O-A2, but which is not identified by current bioinformatic analysis. In a recent study, the structures of six novel siderophores termed fimsbactin A-F have been elucidated and the biosynthesis gene clusters for fimsbactin production have been identified in *A. baylyi* ADP1 and *A. baumannii* strains (ATCC 17978 and 6013150), although BLAST analysis showed that the fimsbactin gene cluster is not present in *A. baumannii* strain ABH12O-A2 (data not shown) \[[@CR61]\].

In the macrophage model, we observed increased expression (not over-expressed in the BALF model: iTRAQ ratio, 1.26) of the Tig factor in the *ex vivo* samples. *De novo* protein folding in *Escherichia coli* is mainly orchestrated by the chaperone trigger factor and by DnaK and GroEL. The ribosome-bound trigger factor is the first chaperone to interact cotranslationally with nascent polypeptides. It has been suggested that a trigger factor homologue in *Streptococcus mutans* is a key regulator of stress tolerance, genetic competence and biofilm formation, all of which are critical virulence properties of this bacterium. In *Listeria monocytogenes*, a trigger factor homologue is involved in the stress response and associated pathogenicity \[[@CR62]--[@CR64]\].

We observed increased expression of the DnaK suppressor protein, which was significant (*p* \< 0.05) in the BALF model, but not in the macrophage model. This protein plays an important role in the virulence of *Salmonella* and *Escherichia coli* \[[@CR65]\].

In the BALF model, expression of the ClpX protein increased (but was not significantly over-expressed (*p* \> 0.05) in the macrophage model). ClpX is required for virulence, biofilm formation and intracellular replication in *Staphylococcus aureus* \[[@CR66]\].

Initial attachment to abiotic surfaces is the first step for colonization and subsequent biofilm formation on *e.g.* ventilator tubing and catheters. In *A.* baumannii 19606, the type I pili encoded by CsuA/BABCDE appears to be involved in this process \[[@CR67]\]. In our host cell-free model (BALF model), the proteins OmpA (iTRAQ ratio = 1.51), CsuA and CsuC were over-expressed, suggesting biofilm activation by the host secretome that defends *A. baumannii* against host on medical devices. Another critical step in the pathogenesis of *A. baumannii* is the ability to adhere to eukaryotic cells, although the mechanisms of adherence are different for abiotic and biotic surfaces. It has been demonstrated that OmpA acts as a virulence factor in *A. baumannii* and has an important role in cell death through both mitochondrial and nuclear targeting \[[@CR68]\]. The OmpA of *A. baumannii* 19606 also plays a partial role in biofilm formation on plastic, but is essential for attachment to biotic surfaces such as *C. albicans* and human alveolar epithelial cells. Interestingly, the absence of these cell appendages also favours bacterial attachment and invasion of epithelial cells. This may be due to greater exposure of other unknown bacterial adhesion and biofilm factors in the absence of pili \[[@CR69]\]. In our macrophage model, OmpA (iTRAQ ratio = 7.80) was over-expressed and both CsuA and CsuC were under-expressed. Together these results suggest that contact between *A. baumannii* cells and macrophages may be an important factor determining underexpression of the CsuA/ BABCDE protein. Elucidation of the complex interactions between *A. baumannii*and both abiotic and biotic surfaces is important for a better understanding of the pathobiology of *A. baumannii* and also for identification of novel targets for the development of new antimicrobial strategies.

In the macrophage model, we observed increased expression of the PaaA protein in the *ex vivo* samples, but we did not observe significant (*p* \> 0.05) repression of the PaaZ protein. In contrast, in the BALF model, we observed repression of PaaZ protein but no modulation (*p* \> 0.05) of the PaaA protein. In the catabolism of phenylacetic acid by some bacteria, PaaA encodes part of the phenylacetic acid---coenzyme A ring hydroxylation system, and opening of the aromatic ring may be performed by PaaZ. In *Burkholderia cenocepacia, PaaA* insertional mutants were attenuated for virulence and interruption of increased virulence of *PaaZ* \[[@CR70]\].

The success of a bacterial infection greatly depends on the ability of the bacteria to use external nutrients. Therefore, the proteolytic and lipolytic activities of extracellular proteins may play key roles in the establishment of *A. baumannii* infection \[[@CR71]\]. In general, in the macrophage model, proteins with proteolytic activity were over-expressed, and in the BALF model, this type of protein was under-expressed. This may be due to continuous production of host proteins in the macrophage model but not in the BALF model as well as to over-expressed amino acid metabolism in the macrophage model and under-expressed amino acid metabolism in the BALF model.

We identified a cyclophilin (PPIase) (AIS06968.1), which was over-expressed in the macrophage model and not modulated in the BALF model. It has been established that PPIases may play a role during bacterial survival against macrophage attack, and it has been suggested that PPIases may act as virulence factors by interacting with some proteins from the host cell membrane, thus helping render the host cell more susceptible to penetration via conformational changes through cis-trans isomerization of peptidyl-prolyl bonds \[[@CR72], [@CR73]\]. These types of proteins have been reported to affect the phagocytosis of *Streptococcus pneumoniae* by macrophages \[[@CR74]\].

In both models, the uncharacterized ABC transporter ATP-binding protein YjjK was over-expressed. The precise role of YjjK, encoding a putative ATP binding protein of an ABC transporter, is not yet known. However, YjjK is required for the entry and survival of *Porphyromonas gingivalis* in gingival epithelial cells \[[@CR75]\]. It has also been suggested that YjjK is involved in *Francisella tularensis* virulence \[[@CR76]\].

Eighteen genes have been identified in *A. baumannii* as being involved in growth on human ascites and shown to be essential for growth and survival during infection \[[@CR77]\]. In the present study, we found 53 % of these essential proteins: 4 of these were over-expressed (OmpF, RpmA, CarA and PyrC), 4 were un-modulated (AroA, AroC, RstA and SecE) and AceE was under-expressed. The present findings are only partly consistent with those of the aforementioned study \[[@CR77]\] as SpsC is not contained in the AbH12O-A2 genome and we did not detect8 of the proteins. However, these differences may be due to the undetected proteins occurring in amounts below the detection/identification level or to differences in the host microenvironment.

When *A. baumannii* infects the host airway, it is present in multiple locations, including in the interstitium between cells, embedded in mucus in the lumen, inside and adhering to macrophages and epithelial cells. Therefore, *A. baumannii* must adapt to multiple microenvironments and may express different proteins, depending on the microenvironment. We examined 2 *ex vivo* models of infection: a host cell-free model in which *A. baumannii* interacts with soluble host components present inside the infected lung, and an immune system cells model, in which *A. baumannii* interacts with macrophages. One limitation of the study is that we only simulated some conditions in the host airways and *A. baumannii* is present in many other microenvironments. Caution must therefore be used in extrapolating results of the present study to the human disease because *A. baumannii* populations that colonize the human airways are probably a mixture of *A. baumannii* from different microenvironments.

The AbH12O-A2 strain yielded over-expressed 'hypothetical proteins'. Induced expression of hypothetical proteins strongly indicates that *A. baumannii* generates host resistance by unknown mechanisms. These genes are obvious candidates for subsequent functional characterization and for research aimed at determining their function within infection processes.

Conclusions {#Sec11}
===========

This study is the first comprehensive overview of the *ex vivo* proteome of the multidrug resistant microbial pathogen *A. baumannii* and provides some insight into the potential role of putative virulence proteins *in vivo*. The *ex vivo* behaviour of *A. baumannii* was compared, for the first time, under different infection conditions---in BALF and in the presence of macrophages---as well as under *in vitro* conditions. A rapid enrichment technique was successfully used, together with MS/MS analysis, to characterize the *ex vivo* proteome of *A. baumannii* and showed that the proteome is significantly different from that of bacteria cultured *in vitro*. The changes in the proteome observed for the strain *A. baumannii* AbH12O-A2 indicate a response to stress resulting from interaction with host and modification of cell wall synthesis. We identified 2 over-expressed virulence-associated proteins with \>15 peptides/protein in both *ex vivo* models (OmpA and an uncharacterized ABC transporter ATP-binding protein YjjK), which appear to be essential for pathogenesis and virulence in the airways. Overall, the data suggest that *A. baumannii* can use a variety of virulence mechanisms that enable it to adapt to and survive in vastly divergent environments. These data are helpful for elucidating the molecular mechanisms associated with the interaction between *A. baumannii* and host and represent an important step towards identification of diagnostic biomarkers, novel drug targets and potential vaccine candidates in the fight against pneumonia caused by *A. baumannii*.

Methods {#Sec12}
=======

Bacterial strain {#Sec13}
----------------

A highly invasive multidrug-resistant (including carbapenems) *Acinetobacter baumannii* clone (AbH12O-A2), which infected more than 300 patients in the 12 de Octubre Hospital (Madrid, Spain) was used in this study.

The annotated sequence for AbH12O-A2 \[GenBank CP009534.1\] is available at the National Center for Biotechnology Information (NCBI) \[[@CR78]\].

Rat model of pneumonia and BALF (bronchoalveolar lavage fluid) {#Sec14}
--------------------------------------------------------------

Male Wistar rats (INIBIC, A Coruña, Spain) of about 350 g weight were used in the experiment. Antibiotic-free pelleted food and water were provided *ad libitum* during the assay. The experiment was approved by the Ethics Committee for Animal Experimentation of A Coruna Hospital. The rats were anaesthetized intraperitoneally with sodium thiopental and were inoculated intratracheally under direct vision with a bacterial suspension, which was prepared as follows: bacteria were grown at 37 °C in LB until an optical density of 0.7 at 600 nm, washed with sterile saline solution and mixed 1:1 with a saline solution of porcine mucin at 10 % (wt/vol). The final inoculum was about 3 × 10^8^ CFUs/rat. At 21 h after inoculation, animals were euthanized by intraperitoneal injection of an overdose of sodium thiopental. The lungs were washed twice with about 45 ml normal saline (0.9 % NaCl). The concentrations of the original bacterial suspensions and of the BALF were determined by the plate count method. The BALF from three animals was centrifuged (3000 × g, 30 min at 4 °C) to remove cells, and the supernatant was filtered through a 0.22 μm membrane (low protein binding Millex-GP polyethersulfone membrane (Millipore, Bedford, U.S.A.)) to remove residual bacteria. Absence of viable bacteria was confirmed by culture on Mueller Hinton (MH) agar plates. BALF was stored at −70 °C for a maximum of 3 months until use.

Histopathology {#Sec15}
--------------

Paraformaldehyde-fixed lung tissue was embedded in paraffin, sectioned and stained with hematoxylin and eosin. Two to four sections from each lung of infected rats were examined.

Incubation of *A. baumannii* in rat BALF {#Sec16}
----------------------------------------

*Acinetobacter baumannii* strain AbH12O-A2 was streaked on MH nutrient agar. A single colony was then inoculated in 5 mL LB and grown overnight at 37 °C with vigorous shaking. 100 mL of LB (10 g/L tryptone + 5 g/L yeast extract dissolved in saline solution instead of water) and 100 ml of modified LB (40 g/L tryptone + 20 g/L yeast extract dissolved in saline solution instead of water + 75 % (v/v) BALF as a physiologically relevant source of host proteins to simulate conditions in the respiratory tract) were inoculated with a 1:100 dilution of the overnight culture and grown simultaneously for 21 h at 37 °C and 5 % CO~2~ without shaking. Three independent biological replicates of each culture were prepared but only 2 were used for the ITRAQ. Cells (OD600 nm = 1.0-1.4) were harvested by centrifugation at 2800 × g for 20 minutes at 4 °C, washed twice by suspending in cold 0.9 % NaCl and centrifuged again under the same conditions. The pellets were frozen and stored at −70 °C until needed.

Macrophage infection with *A. baumannii* {#Sec17}
----------------------------------------

*Acinetobacter baumannii* strain AbH12O-A2 was streaked on MH nutrient agar. A single colony was then inoculated in 5 mL LB and grown overnight at 37 °C with vigorous shaking. The overnight culture was harvested, washed once and resuspended in tissue culture medium: DMEM with glucose and L-glutamine (4.5 g/L dextrose + 3.7 g/L NaHCO~3~ + 0.015 g/L phenol red + 0.110 g/L sodium pyruvate + 0.200 g/L CaCl~2~ + 0.100 mg/L Fe(NO~3~)~3~.9H~2~O + 0.098 g/L MgSO~4~ + 0.400 g/L KCl + 6.400 g/L NaCl + 0.007 g/L i-Inositol + 0.109 g/L NaH~2~PO~4~ + 15 amino acids and vitamins (BioWhittaker Lonza, Verviers, Belgium)) supplemented with 10 % fetal bovine serum and 1 % penicillin/streptomycin. The concentration of bacterial cells was then determined.

To mimic host microbe interactions involving phagocytic immune system cells the RAW 264.7 macrophage-like cell line was plated in cell culture flasks at 3 × 10^7^ cells/flask and incubated overnight at 37 °C with 5 % CO2. Macrophage cells were washed twice with 20 ml/flask of 0.9 % NaCl. The tissue culture medium was then added to each flask, and 1 mL of the *A. baumannii* in the tissue culture medium was added to each flask with a multiplicity of infection of 3 (i.e. 3 times more bacterial cells than macrophages were used). To increase the uptake of *A. baumannii* and synchronize infection, flasks were centrifuged at 250 × g for 5 min at room temperature and then incubated at 37 °C with 5 % CO~2~ for 21 h without shaking. Three independent biological replicates of each culture were prepared but only 2 were used for the ITRAQ. The sample was harvested 21 h post infection. Extracellular bacteria were isolated from infected macrophage cultures. To isolate extracellular bacteria, infected macrophage cultures were washed three times with Hank's buffered salt solution to remove any bacteria that were not inside adherent cells. The harvested sample and the wash solutions were centrifuged (500 × g for 2 min at 4 °C to pellet any nonadherent macrophage cells) and the supernatants were combined. The supernatant was centrifuged (1500 × *g* for 20 min at 4 °C) to pellet the bacteria. The pellet was resuspended in phosphate-buffered saline (PBS) and filtered through a Transwell filter membrane system (3.0-μm pore size; BD Falcon, Erembodegem, Belgium). Macrophage cells were very scarce. Bacteria then were washed twice by suspending them in cold PBS and centrifuging (2800 × g for 20 minutes at 4 °C). The pellets were frozen and stored at −70 °C until needed. Control *A. baumannii* cells were collected, washed and treated in the same way as above but in the absence of macrophages.

Protein extraction {#Sec18}
------------------

The resultant pellet was resuspended in disintegration buffer (7.8 g/L NaH~2~PO~4~, 7.1 g/L Na~2~HPO~4~, 0.247 g/L MgSO~4~.7H~2~O) + protease inhibitor mix (GE Healthcare, Piscataway, USA) + nuclease mix (GE Healthcare, Piscataway, USA) and sonicated on ice for 3 periods of 5 min. The unbroken cells were separated by centrifugation at 1500 × *g* at 4 °C. The supernatant was centrifuged for at least 30 min at 4 °C and 4500 × g before being clarified through a 0.22 μm membrane (low protein binding Millex-GP polyethersulfone membrane from Millipore, Bedford, U.S.A.) to remove the cell debris. Finally, the extract was processed with a 2-DE Cleanup Kit (GE Healthcare, Piscataway, USA), following the manufacturer's instructions. The concentration of protein was measured using the Bio-Rad protein assay (Bio-Rad, Munich, Germany).

iTRAQ labelling and LC-MALDI/TOF analysis {#Sec19}
-----------------------------------------

Labelling, 2-D liquid chromatography and MALDI-TOF/TOF MS analysis of the samples were performed as previously described \[[@CR79]\], and stage tips were used for peptide desalting. Briefly, 30 μg of protein from each condition was reduced, cysteine was blocked, digested with trypsin and labelled with respective isobaric tags using iTRAQ reagent Multiplex kit (AB Sciex Ltd., Foster City, CA), according to the manufacturer's protocol. The sample labelling was as follows: iTRAQ tags 114: control BALF model; iTRAQ tags 115: sample BALF model; iTRAQ tags 116: control macrophage model; iTRAQ tags 117: sample macrophage model. In the first dimension, peptides were fractionated by basic reversed-phase chromatography in a 1200 HPLC system (Agilent) and were collected using a Gilson FC203B fraction collector (Gilson, Middleton, WI). The collected peptide fractions were desalted with the aid of home made stage tips and separated by reversed-phase chromatography at acid pH in a nanoLC system (Tempo, ABSciex, Foster City, CA). The peptides were desalted and concentrated in a trapping column (0.5 × 2 mm, Michrom Bioresources, Auburn, CA) at a flow rate of 15 μL/min for 15 min and loaded onto a C18 column (Integrafit C18, Proteopep II, 75 μm i.d., 15 cm, 5 μm, 300 Å; New Objective, Woburn, MA). Peptides were eluted at a flow rate of 0.35 μL/min during a 2 h linear gradient from 2 to 40 % B (mobile phase A: 0.1 % trifluoroacetic acid, 2 % acetonitrile; mobile phase B: 0.1 % trifluoroacetic acid, 95 % acetonitrile), mixed with α-cyano matrix (4 mg/mL at a flow rate of 1.2 μL/ min), automatically deposited on a MALDI plate using a MALDI spotter (SunCollect, Sunchrome, Friedrichsdorf, Germany) and were finally analyzed in a 4800 TOF/TOF system (ABSciex, Foster City, CA). The chromatograms were composed by 480 spots, each comprising a 15 s deposition. Explorer v.4.2 (ABSciex, Foster City, CA) software (series 4000) was used to generate both the spectra and peak list. Plate model and default calibration of the MALDI plate were performed at a laser voltage of 3400 kV and 1000 shots/spectrum. Samples were automatically analyzed in MS mode at a laser voltage of 3800 kV and 1500 shots/spectrum.

Automated precursor selection was carried out by a Jobwide interpretation method, which selects up to 12 precursors per fraction. The lower threshold of signal to noise (50) and trypsin autolytic peptides and other background ions were excluded. The laser voltage was 4800 kV, and 2000 shots/spectrum were acquired using a medium-range CID collision energy.

LC-MALDI-TOF/TOF data were analyzed using Protein Pilot 4.0 software (ABSciex, Foster City, CA) as the search engine for protein identification. Protein Pilot search parameters were as follows: Cys-alkylation, iodoacetamide; iTRAQ 4plex quantitation mode, biological modifications; digestion with trypsin; All searches were performed against the non-redundant NCBI library ([http://ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov/)) database comprising annotated proteins of *Acinetobacter baumannii* AbH12O-A2 and pMMA2 plasmid. The search effort comprised thorough ID and detection protein threshold of unused ProtScore (Conf \> 1.3 (95.0 %)). The scoring model was defined by the Paragon algorithm. Bias and background correction were applied to correct experimental differences in total amount of protein used in the experiment and label interference, respectively. Proteins showing sample/control protein expression ratios below 0.5 or above 1.5 (p \< 0.05) were considered to be respectively under- or over-expressed and were selected for further analysis.

Purity of the starting material {#Sec20}
-------------------------------

The MS analysis of *A. baumannii* in BALF model and in macrophage model did not reveal any of the most abundant BALF proteins (serum albumin, IgG, IgA, transferrin, haptoglobin and antitrypsin) \[[@CR80]\], nor the most abundant protein component of alveolar surfactant (surfactant protein A) \[[@CR81]\], nor the very abundant enzymes phosphoglycerate kinase (cytosol of macrophages) and metallopeptidase 9 (macrophage membranes) \[[@CR82]\]. We therefore, concluded that the starting material for the *A. baumannii* proteome analysis was not (or only minimally) contaminated with host material. This was not surprising because BALF proteins sediment at much higher centrifugation speeds than bacteria and because we could barely see nonadherent macrophage cells (see section "Macrophage infection with *A. baumannii*").

Bioinformatics {#Sec21}
--------------

Protein function was determined by [http://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/).

HHomp, <http://toolkit.tuebingen.mpg.de/hhomp>\# was used for the prediction of outer membrane proteins.

The presence of export signals was predicted by use of a combination of algorithms (SignalP 4.1 (<http://www.cbs.dtu.dk/services/SignalP/>), Phobius (<http://phobius.sbc.su.se/>), PrediSi (<http://www.predisi.de/>), TatP 1.0 ([www.cbs.dtu.dk/services/TatP-1.0](http://www.cbs.dtu.dk/services/TatP-1.0)), Tatfind 1.4 (<http://signalfind.org/tatfind.html>), SecretomeP 2.0 ([www.cbs.dtu.dk/services/SecretomeP](http://www.cbs.dtu.dk/services/SecretomeP)), TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>), DAS-TMfilter (<http://www.enzim.hu/DAS/DAS.html>), LipoP 1.0 ([www.cbs.dtu.dk/services/LipoP](http://www.cbs.dtu.dk/services/LipoP)), DOLOP (<http://www.mrc-lmb.cam.ac.uk/genomes/dolop/>), and LIPO (<http://services.cbu.uib.no/tools/lipo>)). \[see Additional file [3](#MOESM3){ref-type="media"}\].

RNA extraction and RT-PCR {#Sec22}
-------------------------

Total RNA was extracted using the High Pure RNA isolation kit (Roche, Mannheim, Germany), according to the manufacturer's instructions. PCR without reverse transcriptase confirmed the absence of DNA. Templates of 100 ng of total RNA were used in the target gene studies. Real-time PCR analysis of gene expression was performed in duplicate with specific internal oligonucleotide primers and the TaqMan probe (Universal ProbeLibrary-UPL, Roche, Mannheim, Germany). All primers and UPL probes used in the RT-PCR study are shown in Additional file [4](#MOESM4){ref-type="media"}.

Availability of supporting data {#Sec23}
-------------------------------

The proteomics data sets supporting the results of this article are included within the article and its Additional file [5](#MOESM5){ref-type="media"}.

Additional files {#Sec24}
================

Additional file 1:**Workflow of the proteomic experiment.** Strategy used to recover and identify the proteins of *A. baumannii* in 2 ex vivo models for proteomic analysis.Additional file 2:**Histopathology shows signs of consolidated pneumonia in infected animals.** A), C) and E) representative low (×4) - and B), D) and F) high (×40)-power histological sections of lungs from three rats infected with *A. baumannii* for 21 h. A -- F haematoxylin and eosin staining.Additional file 3:**Prediction of exoproteins. This figure indicates the sequential use of different algorithms into a majority vote decision.** Coding sequences were scanned for the presence of signal peptide specific to Sec pathway and Tat pathway. Coding sequences exhibiting no signal peptide were screened as potential nonclassically secreted proteins using SecretomeP 2.0. Proteins predicted as secreted were then asked for the presence of cell-envelope retention domain and erased from the output in positive case. Y, yes; N, no.Additional file 4:**RT-PCR analysis of different genes. Primers and Univesal ProbeLibrary (UPL, Roche) probes used in this study.**Additional file 5:**Protein identification data.** Excel workbook containing 2 worksheets with the complete report for the proteins in both models exported from Protein Pilot software.

BALF

:   Bronchoalveolar lavage fluid
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